Expertise in
7
conditions

Dr. Cynthia J. Wetmore

Hematology | Oncology
St. Luke's Hospital Of Duluth
1012 E 2nd St, 
Duluth, MN 
Expertise in
7
conditions
St. Luke's Hospital Of Duluth
1012 E 2nd St, 
Duluth, MN 

Overview

Cynthia Wetmore is a Hematologist and an Oncologist practicing medicine in Duluth, Minnesota.

Dr. Wetmore is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Brain Stem Cancer, Brain Tumor, Glioma, and Posterior Fossa Tumor.

She is actively involved in clinical research, co-authoring 37 peer reviewed articles and participating in 17 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatrics in MS

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

St. Luke's Hospital of Duluth
1012 E 2nd St, Duluth, MN 55805

Additional Areas of Focus

Dr. Wetmore has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Alisertib, Methotrexate, Cisplatin, Carboplatin, Cyclophosphamide, Etoposide, Topotecan, Vincristine
Study Phase: Phase 2
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2026
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Enrollment Status: Active_not_recruiting
Publish Date: June 23, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 1/Phase 2
AflacST1502: A Phase II Study of Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
AflacST1502: A Phase II Study of Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 02, 2026
Intervention Type: Drug
Study Drugs: Sirolimus, Celecoxib, Etoposide, Cyclophosphamide
Study Phase: Phase 2
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Irinotecan, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 1
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Drug, Other, Radiation
Study Drug: Adavosertib
Study Phase: Phase 1
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Drug, Other
Study Phase: Phase 1
View 9 Less Clinical Trials

37 Total Publications

Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
Journal: Neuro-oncology
Published: June 02, 2022
Similar Doctors
Expertise in
33
conditions
Dr. Homam Alkaied
Hematology | Oncology
Expertise in
33
conditions
Dr. Homam Alkaied
Hematology | Oncology
Referral may be required

Office

1001 E Superior St Ste L101, 
Duluth, MN 
 (4.3 miles away)
218-249-3081
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Homam Alkaied is a Hematologist and an Oncologist practicing medicine in Duluth, Minnesota. Dr. Alkaied is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Multiple Myeloma, Paget Disease of the Breast, and Pleuropulmonary Blastoma. Dr. Alkaied is currently accepting new patients.

Expertise in
12
conditions
Dr. Roberto J. Fernandez
Hematology | Oncology
Expertise in
12
conditions
Dr. Roberto J. Fernandez
Hematology | Oncology
Referral may be required

St Luke's Nephrology Associates

1001 E Superior St, 
Duluth, MN 
 (0.1 miles away)
218-249-3081
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Roberto Fernandez is a Hematologist and an Oncologist practicing medicine in Duluth, Minnesota. Dr. Fernandez is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Neuroendocrine Tumor, and Chronic Lymphocytic Leukemia (CLL). Dr. Fernandez is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Essentia Health-Duluth Clinic 1st Street (Building A)

420 E 1st St, 
Duluth, MN 
 (0.5 miles away)
218-212-8447
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Nikcevich is a Hematologist practicing medicine in Duluth, Minnesota. Dr. Nikcevich is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Large-Cell Immunoblastic Lymphoma, Richter Syndrome, and Chronic B-Cell Leukemia (CBCL). Dr. Nikcevich is currently accepting new patients.

Frequently Asked Questions about Dr. Cynthia J. Wetmore

How do I make an appointment with Dr. Cynthia J. Wetmore?

You can book an appointment with Dr. Cynthia J. Wetmore by calling their office at 218-249-5555. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Cynthia J. Wetmore a top-rated expert for Brain Stem Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Cynthia J. Wetmore is classified as an Advanced expert for Brain Stem Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Cynthia J. Wetmore specialize in?

While Dr. Cynthia J. Wetmore is a Hematology, they have specific expertise in Brain Stem Cancer, Brain Tumor, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Cynthia J. Wetmore participate in research or clinical trials?

Yes. Dr. Cynthia J. Wetmore has published 37 articles and abstracts on conditions like Brain Stem Cancer. You can view a list of Dr. Cynthia J. Wetmore's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Cynthia J. Wetmore accept my insurance?

Dr. Cynthia J. Wetmore accepts most major insurance plans, including Blue Cross Blue Shield and Medicaid. We recommend calling the office directly at 218-249-5555 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wetmore's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile